open access

Vol 25, No 2 (2018)
Original articles — Basic science and experimental cardiology
Published online: 2017-10-18
Get Citation

Diagnostic performance of microRNA-133a in acute myocardial infarction: A meta-analysis

Lei Zhu, Fuyuan Liu, Hua Xie, Jin Feng
DOI: 10.5603/CJ.a2017.0126
·
Pubmed: 29064535
·
Cardiol J 2018;25(2):260-267.

open access

Vol 25, No 2 (2018)
Original articles — Basic science and experimental cardiology
Published online: 2017-10-18

Abstract

 Background: The aim of this study was to evaluate the diagnostic performance of microRNA-133a in the diagnosis of acute myocardial infarction (AMI).

Methods: Major databases including PubMed, Embase and the Cochrane Library were searched for case-controlled studies comparing AMI and non-AMI patients. The outcome was evaluated by the relative expression of microRNA-133a in plasma or serum. The Mantel-Haenszel odds ratio (OR) was calculated using a fixed-effects model meta-analysis for the outcome. The primary outcomes of interest were pooled sensitivity, specificity and diagnostic accuracy of microRNA-133a for AMI.

Results: Out of 137 identified related articles, 10 were found to conform with the inclusion and ex­clusion criteria of the study. The 10 case-controlled studies contained complete data for 1,074 patients (with no restrictions of race, age or sex), and a database containing 137 patients from the registry of each study. In addition to low heterogeneity, a statistically significant increase was found in overall microRNA-133a expression between AMI vs. non-AMI; the pooled OR was 22.84 (95% confidence interval [CI] 13.87–37.63), sensitivity was 0.84 (95% CI 0.75–0.90), specificity was 0.82 (95% CI 0.74–0.89) and area under curve (AUC) was 0.90 (95% CI 0.87–0.92).

Conclusions: Based on the meta-analysis of ten case-controlled studies including 1,074 patients,it was found that the level of microRNA-133a in blood serum or plasma maybe used as a diagnostic biomarker of AMI.

Abstract

 Background: The aim of this study was to evaluate the diagnostic performance of microRNA-133a in the diagnosis of acute myocardial infarction (AMI).

Methods: Major databases including PubMed, Embase and the Cochrane Library were searched for case-controlled studies comparing AMI and non-AMI patients. The outcome was evaluated by the relative expression of microRNA-133a in plasma or serum. The Mantel-Haenszel odds ratio (OR) was calculated using a fixed-effects model meta-analysis for the outcome. The primary outcomes of interest were pooled sensitivity, specificity and diagnostic accuracy of microRNA-133a for AMI.

Results: Out of 137 identified related articles, 10 were found to conform with the inclusion and ex­clusion criteria of the study. The 10 case-controlled studies contained complete data for 1,074 patients (with no restrictions of race, age or sex), and a database containing 137 patients from the registry of each study. In addition to low heterogeneity, a statistically significant increase was found in overall microRNA-133a expression between AMI vs. non-AMI; the pooled OR was 22.84 (95% confidence interval [CI] 13.87–37.63), sensitivity was 0.84 (95% CI 0.75–0.90), specificity was 0.82 (95% CI 0.74–0.89) and area under curve (AUC) was 0.90 (95% CI 0.87–0.92).

Conclusions: Based on the meta-analysis of ten case-controlled studies including 1,074 patients,it was found that the level of microRNA-133a in blood serum or plasma maybe used as a diagnostic biomarker of AMI.

Get Citation

Keywords

diagnostic accuracy/value/performance, acute myocardial infarction, microRNA-133a/miR-133a, meta-analysis

About this article
Title

Diagnostic performance of microRNA-133a in acute myocardial infarction: A meta-analysis

Journal

Cardiology Journal

Issue

Vol 25, No 2 (2018)

Pages

260-267

Published online

2017-10-18

DOI

10.5603/CJ.a2017.0126

Pubmed

29064535

Bibliographic record

Cardiol J 2018;25(2):260-267.

Keywords

diagnostic accuracy/value/performance
acute myocardial infarction
microRNA-133a/miR-133a
meta-analysis

Authors

Lei Zhu
Fuyuan Liu
Hua Xie
Jin Feng

References (31)
  1. Zhou C, Cui Q, Su G, et al. MicroRNA-208b Alleviates Post-Infarction Myocardial Fibrosis in a Rat Model by Inhibiting GATA4. Med Sci Monit. 2016; 22: 1808–1816.
  2. White HD, Chew DP. Acute myocardial infarction. Lancet. 2008; 372(9638): 570–584.
  3. Huss A, Spoerri A, Egger M, et al. Aircraft Noise, Air Pollution, and Mortality From Myocardial Infarction. Epidemiology. 2010; 21(6): 829–836.
  4. Cleutjens JP, Verluyten MJ, Smiths JF, et al. Collagen remodeling after myocardial infarction in the rat heart. Am J Pathol. 1995; 147(2): 325–338.
  5. Sun J, Rong Z, Wugeti N, et al. Experimental evaluation of myocardial fibrosis in a rapid atrial pacing model in New Zealand rabbits using quantitative analysis of ultrasonic backscatter. Med Sci Monit. 2014; 20: 1884–1889.
  6. Yang S, Piao J, Jin L, et al. Does pretreatment of bone marrow mesenchymal stem cells with 5-azacytidine or double intravenous infusion improve their therapeutic potential for dilated cardiomyopathy? Med Sci Monit Basic Res. 2013; 19: 20–31.
  7. Wang L, Li G, Wang Z, et al. Elevated expression of C3G protein in the peri-infarct myocardium of rats. Med Sci Monit Basic Res. 2013; 19: 1–5.
  8. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116(2): 281–297.
  9. Dong S, Cheng Y, Yang J, et al. MicroRNA expression signature and the role of microRNA-21 in the early phase of acute myocardial infarction. J Biol Chem. 2009; 284(43): 29514–29525.
  10. Ai J, Zhang R, Li Y, et al. Circulating microRNA-1 as a potential novel biomarker for acute myocardial infarction. Biochem Biophys Res Commun. 2010; 391(1): 73–77.
  11. Gidlöf O, Smith JG, Miyazu K, et al. Circulating cardio-enriched microRNAs are associated with long-term prognosis following myocardial infarction. BMC Cardiovasc Disord. 2013; 13: 12.
  12. Kuwabara Y, Ono K, Horie T, et al. Increased microRNA-1 and microRNA-133a levels in serum of patients with cardiovascular disease indicate myocardial damage. Circ Cardiovasc Genet. 2011; 4(4): 446–454.
  13. Ke-Gang J, Zhi-Wei Li, Xin Z, et al. Evaluating diagnostic and prognostic value of plasma miRNA133a in acute chest pain patients undergoing coronary angiography. Medicine (Baltimore). 2016; 95(17): e3412.
  14. Gacoń J, Kabłak-Ziembicka A, Stępień E, et al. Decision-making microRNAs (miR-124, -133a/b, -34a and -134) in patients with occluded target vessel in acute coronary syndrome. Kardiol Pol. 2016; 74(3): 280–288.
  15. Devaux Y, Mueller M, Haaf P, et al. Diagnostic and prognostic value of circulating microRNAs in patients with acute chest pain. J Intern Med. 2015; 277(2): 260–271.
  16. Ji Q, Jiang Q, Yan W, et al. Expression of circulating microRNAs in patients with ST segment elevation acute myocardial infarction. Minerva Cardioangiol. 2015; 63(5): 397–402.
  17. Jaguszewski M, Osipova J, Ghadri JR, et al. A signature of circulating microRNAs differentiates takotsubo cardiomyopathy from acute myocardial infarction. Eur Heart J. 2014; 35(15): 999–1006.
  18. Gidlöf O, Andersson P, van der Pals J, et al. Cardiospecific microRNA plasma levels correlate with troponin and cardiac function in patients with ST elevation myocardial infarction, are selectively dependent on renal elimination, and can be detected in urine samples. Cardiology. 2011; 118(4): 217–226.
  19. Wang R, Li N, Zhang Y, et al. Circulating microRNAs are promising novel biomarkers of acute myocardial infarction. Intern Med. 2011; 50(17): 1789–1795.
  20. Wang GK, Zhu JQ, Zhang JT, et al. Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur Heart J. 2010; 31(6): 659–666.
  21. Goren Y, Meiri E, Hogan C, et al. Relation of reduced expression of MiR-150 in platelets to atrial fibrillation in patients with chronic systolic heart failure. Am J Cardiol. 2014; 113(6): 976–981.
  22. Schlosser K, White RJ, Stewart DJ. miR-26a linked to pulmonary hypertension by global assessment of circulating extracellular microRNAs. Am J Respir Crit Care Med. 2013; 188(12): 1472–1475.
  23. Peng L, Chun-guang Q, Bei-fang Li, et al. Clinical impact of circulating miR-133, miR-1291 and miR-663b in plasma of patients with acute myocardial infarction. Diagn Pathol. 2014; 9(1): 89.
  24. Li YQ, Zhang MF, Wen HY, et al. Comparing the diagnostic values of circulating microRNAs and cardiac troponin T in patients with acute myocardial infarction. Clinics (Sao Paulo). 2013; 68(1): 75–80.
  25. Cao H, Shockey JM. Comparison of TaqMan and SYBR Green qPCR methods for quantitative gene expression in tung tree tissues. J Agric Food Chem. 2012; 60(50): 12296–12303.
  26. Wang F, Long G, Zhao C, et al. Plasma microRNA-133a is a new marker for both acute myocardial infarction and underlying coronary artery stenosis. J Transl Med. 2013; 11: 222.
  27. Widera C, Gupta SK, Lorenzen JM, et al. Diagnostic and prognostic impact of six circulating microRNAs in acute coronary syndrome. J Mol Cell Cardiol. 2011; 51(5): 872–875.
  28. Matsumoto S, Sakata Y, Nakatani D, et al. A subset of circulating microRNAs are predictive for cardiac death after discharge for acute myocardial infarction. Biochem Biophys Res Commun. 2012; 427(2): 280–284.
  29. Wang R, Li N, Zhang Y, et al. Circulating microRNAs are promising novel biomarkers of acute myocardial infarction. Intern Med. 2011; 50(17): 1789–1795.
  30. Devaux Y, Vausort M, McCann GP, et al. A panel of 4 microRNAs facilitates the prediction of left ventricular contractility after acute myocardial infarction. PLoS One. 2013; 8(8): e70644.
  31. Devaux Y, Vausort M, Azuaje F, et al. Low levels of vascular endothelial growth factor B predict left ventricular remodeling after acute myocardial infarction. J Card Fail. 2012; 18(4): 330–337.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl